Evidence map›Paper›PMID 18257117›Full record

ArticleJournal of Zhejiang University. Science. B2007

Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.

Ai-jun Liu, Bungo Furusato, Lakshmi Ravindranath, Yong-mei Chen, Vasanta Srikantan, David G McLeod, Gyorgy Petrovics, Shiv Srivastava

Open access · bronzeAbstract read
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Prostate cancer: the need for biomarkers and new therapeutic targets.Journal of Zhejiang University. Science. B · 2014
    Review
  8. Article
  9. Article
  10. Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.American journal of physiology. Cell physiology · 2011
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Ai-jun LiuDepartment of Pathology, Chinese PLA General Hospital, Beijing 100853, China. aliu301@yahoo.com.cn
Bungo Furusato
Lakshmi Ravindranath
Yong-mei Chen
Vasanta Srikantan
David G McLeod
Gyorgy Petrovics
Shiv Srivastava
Uniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate molecular alterations associating with prostate carcinoma progression and potentially provide information toward more accurate prognosis/diagnosis.

methodsA set of laser captured microdissected (LCM) specimens from 300 prostate cancer (PCa) patients undergoing radical prostatectomy (RP) were defined. Ten patients representing "aggressive" PCa, and 10 representing "non-aggressive" PCa were selected based on prostate-specific antigen (PSA) recurrence, Gleason score, pathological stage and tumor cell differentiation, with matched patient age and race between the two groups. Normal and neoplastic prostate epithelial cells were collected with LCM from frozen tissue slides obtained from the RP specimens. The expressions of a panel of genes, including NPY, PTEN, AR, AMACR, DD3, and GSTP1, were measured by quantitative real-time RT-PCR (TaqMan), and correlation was analyzed with clinicopathological features.

resultsThe expressions of AMACR and DD3 were consistently up-regulated in cancer cells compared to benign prostate epithelial cells in all PCa patients, whereas GSTP1 expression was down regulated in each patient. NPY, PTEN and AR exhibited a striking difference in their expression patterns between aggressive and non-aggressive PCas (P=0.0203, 0.0284, and 0.0378, respectively, Wilcoxon rank sum test). The lower expression of NPY showed association with "aggressive" PCas based on a larger PCa patient cohort analysis (P=0.0037, univariate generalized linear model (GLM) analysis).

conclusionDespite widely noted heterogeneous nature of PCa, gene expression alterations of AMACR, DD3, and GSTP1 in LCM-derived PCa epithelial cells suggest for common underlying mechanisms in the initiation of PCa. Lower NPY expression level is significantly associated with more aggressive clinical behavior of PCa; PTEN and AR may have potential in defining PCa with aggressive clinical behavior. Studies along these lines have potential to define PCa-associated gene expression alterations and likely co-regulation of genes/pathways critical in the biology of PCa onset/progression.

Indexed as

Antigens, NeoplasmGene Expression Regulation, NeoplasticGlutathione S-Transferase piHumansMaleNeuropeptide YProstatic NeoplasmsPTEN PhosphohydrolaseRacemases and EpimerasesReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSensitivity and SpecificityTime Factorsalpha-methylacyl-CoA racemaseAntigens, NeoplasmGlutathione S-Transferase piGSTP1 protein, humanNeuropeptide Yprostate cancer antigen 3, humanPTEN PhosphohydrolasePTEN protein, humanRacemases and EpimerasesReceptors, AndrogenRNA, Messenger

Identifiers

PMID18257117
PMCPMC2100155
OpenAlexW2017828300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.